Company
Revolution Medicines
On Target to Outsmart Cancer
- Business model
- B2B
- Customers
- patients living with RAS-addicted cancers
- Legal name
- Revolution Medicines, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Our mission is to revolutionize treatment for patients with RAS-addicted cancers through the discovery, development and delivery of innovative, targeted medicines.
Funding snapshot
- Total raised
- $204MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $100M2019-06-05
Funding rounds
- Round, 2019
- $100M2019-06-05, SEC form D sold, 34 investors
- Round, 2018
- $56.4M2018-03-23, SEC form D sold, 18 investors
- Round, 2014
- $47.5M2014-12-10, SEC form D sold, 4 investors
Products
- Web
- investigational RAS(ON) inhibitors
- Web
- RAS(ON) inhibitors
Loading relationship preview